T. Rowe Price Associates’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $122K | Buy |
|
|||||
|
2023
Q4 | – | Sell |
|
|||||
|
2023
Q3 | $131K | Buy |
|
|||||
|
2023
Q2 | – | Sell |
|
|||||
|
2023
Q1 | $6.58M | Sell |
|
|||||
|
2022
Q4 | $8.11M | Sell |
|
|||||
|
2022
Q3 | $12.5M | Buy |
|
|||||
|
2022
Q2 | $8.9M | Sell |
|
|||||
|
2022
Q1 | $13.7M | Sell |
|
|||||
|
2021
Q4 | $20.5M | Buy |
|
|||||
|
2021
Q3 | $14.9M | Buy |
|
|||||
|
2021
Q2 | $11.1M | Sell |
|
|||||
|
2021
Q1 | $42.6M | Sell |
|
|||||
|
2020
Q4 | $40.5M | Sell |
|
|||||
|
2020
Q3 | $44.6M | Sell |
|
|||||
|
2020
Q2 | $64.4M | Sell |
|
|||||
|
2020
Q1 | $69.7M | Sell |
|
|||||
|
2019
Q4 | $86.3M | Sell |
|
|||||
|
2019
Q3 | $93.4M | Buy |
|
|||||
|
2019
Q2 | $129M | Buy |
|
|||||
|
2019
Q1 | $131M | Buy |
|
|||||
|
2018
Q4 | $76M | Buy |
|
|||||
|
2018
Q3 | $90.9M | Buy |
|
|||||
|
2018
Q2 | $99.2M | Buy |
|
|||||
|
2018
Q1 | $25.8M | Sell |
|
|||||
|
2017
Q4 | $21.8M | Buy |
|
|||||
|
2017
Q3 | $4.79M | Buy |
|